2026-10-30 08:30:26 UTC#543878duplicateconfirmednews
KYMR stock news
KYMR stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-29 12:27:03 UTC#537231newconfirmednews
Kymera Therapeutics, Inc. Q3 2026 earnings call begins
2026-10-29 11:17:19 UTC#536616newconfirmeddata release
Kymera Therapeutics Q3 2026 GAAP EPS of -$1.32 misses analyst estimates by $0.05
2026-10-29 11:07:22 UTC#536553newconfirmednews
Kymera Therapeutics reports positive Phase 1 data for KT-579; cash runway extended into 2029
2026-10-28 18:27:46 UTC#531304newforecastanalysis
Kymera Therapeutics Q3 2026 Earnings Preview
2026-10-27 12:57:00 UTC#521469newconfirmednews
Morgan Stanley raises Kymera Therapeutics price target to $146 from $135, maintains Overweight rating
2026-10-09 11:24:00 UTC#437886newconfirmednews
Raymond James initiates coverage of Kymera Therapeutics (KYMR) at Outperform
dow_jonesimportance 0.30trust 0.70Kymera Therapeutics, Inc. +0.40Raymond James Financial, Inc. +0.40
2026-10-05 19:32:00 UTC#415530newconfirmednews
Citigroup maintains Buy rating on Kymera Therapeutics (KYMR)
2026-09-22 10:54:00 UTC#347989newconfirmednews
Stifel raises Kymera Therapeutics (KYMR) price target to $152 from $132, maintains Buy
2026-09-21 11:28:15 UTC#342177newconfirmednews
Kymera Therapeutics STAT6 program advances toward Phase III; BofA raises price target to $144
tradingviewimportance 0.30trust 0.60Kymera Therapeutics, Inc. +0.50Bank of America Corporation +0.40KT-579 +0.30+1 entities
2026-09-15 13:37:55 UTC#314212duplicateconfirmednews
Kymera Therapeutics highlights clinical progress for KT-621 STAT6 degrader in atopic dermatitis
2026-09-15 12:51:04 UTC#313816newconfirmednews
Kymera Therapeutics reports rapid clinical progress for KT-621 in atopic dermatitis
2026-09-14 21:10:11 UTC#310168newconfirmednews
Kymab reports STAT6 and IRF5 clinical progress, with phase IIb STAT6 data expected by year-end
2026-09-14 17:57:00 UTC#309230newconfirmednews
B of A Securities raises Kymera Therapeutics (KYMR) price target to $144 from $123, maintains Buy
2026-09-10 16:52:30 UTC#293860duplicateconfirmednews
Kymab (KYMR) reiterates 2026 data readout timeline for oral STAT6 and IRF5 immunology programs
2026-09-10 16:31:43 UTC#293707newconfirmednews
Kymab (KYMR) advances oral immunology pipeline with STAT6 and IRF5 programs nearing data readouts
2026-09-10 13:45:00 UTC#292615newconfirmednews
Wolfe Research upgrades Kymera Therapeutics (KYMR) to Outperform from Peer Perform
2026-09-04 22:10:03 UTC#270694newconfirmednews
Kymera Therapeutics CLO Brian Adams sells $744K in shares for tax obligations
2026-08-27 13:53:00 UTC#229481newconfirmednews
Wells Fargo raises Kymera Therapeutics (KYMR) price target to $151 from $116, maintains Overweight
2026-08-05 13:31:41 UTC#130311duplicateconfirmednews